Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00540787 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
A Phase 4 study of Paroxysmal Atrial Fibrillation, sponsored by Biosense Webster.
- Completed
- Registry status
- Phase 4
- Development phase
- 112
- Enrollment target
- 6
- Study locations
NCT00540787 is a Phase 4 study of Paroxysmal Atrial Fibrillation that has completed, run by Biosense Webster. The registered enrollment target is 112 participants, below the 854-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (87% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT00540787, a Phase 4 study of Paroxysmal Atrial Fibrillation, has completed, sponsored by Biosense Webster.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 112 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to compare radiofrequency catheter ablation and antiarrhythmic drug treatment for the maintenance of sinus rhythm in paroxysmal atrial fibrillation patients.
Conditions Studied
Interventions
- DEVICE Radiofrequency ablation, antiarrhythmic drugs
- DRUG Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs
- DEVICE ThermoCool Radiofrequency Catheter
Study Locations (6)
Other
- Hopital Lariboisiere - Paris
- Hopital Cantonal de Geneve - Geneva
Alabama
- University of Alabama, Birmingham - Birmingham
Massachusetts
- Massachusetts General Hospital - Boston
Ohio
- Mid-Ohio Cardiology - Columbus
Paris
- Hôpital Haut Lèvêque - Pessac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2003-08-01 |
| Est. Completion | 2006-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00540787
The ClinicalTrials.gov registry entry for NCT00540787 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 854-participant average among 24 other Paroxysmal Atrial Fibrillation trials with a reported enrollment target (87% lower). The listed sponsor is Biosense Webster, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paroxysmal Atrial Fibrillation appearing as the primary indexed condition, and to 3 interventions - of which Radiofrequency ablation, antiarrhythmic drugs is the first listed.
NCT00540787 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Other, Alabama, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00540787 about?
NCT00540787 is a clinical study titled "A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation". The purpose of this study is to compare radiofrequency catheter ablation and antiarrhythmic drug treatment for the maintenance of sinus rhythm in paroxysmal atrial fibrillation patients.
What is the current status of trial NCT00540787?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 112 participants. The study started on 2003-08-01. Estimated completion is 2006-06-01.
What conditions does trial NCT00540787 study?
This clinical trial studies the following conditions: Paroxysmal Atrial Fibrillation.
What interventions are being tested in trial NCT00540787?
The interventions under investigation include: Radiofrequency ablation, antiarrhythmic drugs (DEVICE), Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs (DRUG), ThermoCool Radiofrequency Catheter (DEVICE).
Who is sponsoring clinical trial NCT00540787?
This trial is sponsored by Biosense Webster, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00540787 being conducted?
This trial has 6 study locations across Alabama, Massachusetts, Ohio, Paris. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias
RECRUITING · Phase 4
-
Evaluation of VISITAG SURPOINT™ Module With External Processing Unit (EPU)
COMPLETED · Phase 4
-
ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients
RECRUITING · NA
-
Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB)
RECRUITING
-
STOP AF First Post-Approval Study
RECRUITING
-
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.